"Ozempic breath" is boosting Hershey's sales of mints and gum

Candy elephantine Hershey is getting a income boost from an unexpected user segment: users of GLP-1 weight-loss drugs.

Hershey CEO Kirk Tanner said in the company's first-quarter net telephone connected Thursday that portion appetite suppressants are starring customers to devour smaller portions of fashionable snacks, the drugs are besides boosting request for enactment fresheners. 

The institution has "seen beardown request for gum and mint products arsenic the class benefits from functional snacking tailwinds, including GLP-1 adoption," Tanner said. He noted that income for the company's Ice Breakers mint and gum marque accrued 8% implicit the quarter. 

One imaginable explanation: Along with slimming waistlines, drugs similar Ozempic and Wegovy sometimes nutrient the broadside effect of atrocious breath, according to aesculapian professionals. 

"Ozempic enactment refers to a fishy odor successful burps oregon atrocious breath," Dr. Neha Lalani told aesculapian accusation supplier Healthline.

GLP-1 makers don't see atrocious breath, besides known arsenic halitosis, arsenic a broadside effect of the drugs. Doctors besides caution that it's not a objective diagnosis and that the drugs' effects connected patients' oral hygiene are being studied.  

In 1 clinical trial, the shaper of Ozempic and Wegovy, Novo Nordisk, recovered that astir 9% of radical taking GLP-1 medications reported "eructation," amended known arsenic burping. More than 40% reported nausea, and astir 25% reported vomiting arsenic a broadside effect of the drugs. 

Edited by Alain Sherter

In:

• Hershey's
• Ozempic